- Home
- VRAR vs SCYX Comparison
VRAR vs SCYX Comparison
Compare VRAR & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAR
- SCYX
- Stock Information
- Founded
- VRAR 2016
- SCYX 1999
- Country
- VRAR United States
- SCYX United States
- Employees
- VRAR N/A
- SCYX N/A
- Industry
- VRAR Retail: Computer Software & Peripheral Equipment
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- VRAR Technology
- SCYX Health Care
- Exchange
- VRAR Nasdaq
- SCYX Nasdaq
- Market Cap
- VRAR 33.3M
- SCYX 28.5M
- IPO Year
- VRAR 2021
- SCYX 2014
- Fundamental
- Price
- VRAR $1.47
- SCYX $0.70
- Analyst Decision
- VRAR Strong Buy
- SCYX
- Analyst Count
- VRAR 1
- SCYX 0
- Target Price
- VRAR $2.62
- SCYX N/A
- AVG Volume (30 Days)
- VRAR 109.7K
- SCYX 138.2K
- Earning Date
- VRAR 05-15-2025
- SCYX 08-07-2025
- Dividend Yield
- VRAR N/A
- SCYX N/A
- EPS Growth
- VRAR N/A
- SCYX N/A
- EPS
- VRAR N/A
- SCYX N/A
- Revenue
- VRAR $8,756,789.00
- SCYX $2,630,000.00
- Revenue This Year
- VRAR $6.59
- SCYX $463.61
- Revenue Next Year
- VRAR $30.43
- SCYX $310.80
- P/E Ratio
- VRAR N/A
- SCYX N/A
- Revenue Growth
- VRAR N/A
- SCYX N/A
- 52 Week Low
- VRAR $0.50
- SCYX $0.66
- 52 Week High
- VRAR $7.00
- SCYX $2.29
- Technical
- Relative Strength Index (RSI)
- VRAR 52.95
- SCYX 38.69
- Support Level
- VRAR $1.31
- SCYX $0.67
- Resistance Level
- VRAR $1.38
- SCYX $0.75
- Average True Range (ATR)
- VRAR 0.11
- SCYX 0.04
- MACD
- VRAR 0.01
- SCYX 0.00
- Stochastic Oscillator
- VRAR 66.67
- SCYX 33.06
About VRAR The Glimpse Group Inc.
The Glimpse Group Inc is a diversified Virtual and Augmented Reality platform company, comprised of multiple VR and AR software and services companies, and designed with the specific purpose of cultivating companies in the emerging VR/AR industry.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.